Cargando…
Concerning FDA approval of trilaciclib (Cosela) in extensive-stage small-cell lung cancer
Trilaciclib is a recently approved cyclin-dependent kinase 4/6 inhibitor that is designed to decrease the incidence of chemotherapy-induced myelosuppression in adult patients with extensive-stage small-cell lung cancer receiving chemotherapy. Currently, this first-in-class therapy raises two open is...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Neoplasia Press
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379686/ https://www.ncbi.nlm.nih.gov/pubmed/34419683 http://dx.doi.org/10.1016/j.tranon.2021.101206 |